| Literature DB >> 29183348 |
Katharina Holland1, Ioannis Sechopoulos2, Ritse M Mann2, Gerard J den Heeten3, Carla H van Gils4, Nico Karssemeijer2.
Abstract
BACKGROUND: In mammography, breast compression is applied to reduce the thickness of the breast. While it is widely accepted that firm breast compression is needed to ensure acceptable image quality, guidelines remain vague about how much compression should be applied during mammogram acquisition. A quantitative parameter indicating the desirable amount of compression is not available. Consequently, little is known about the relationship between the amount of breast compression and breast cancer detectability. The purpose of this study is to determine the effect of breast compression pressure in mammography on breast cancer screening outcomes.Entities:
Keywords: Breast cancer screening; Breast compression; Mammography; Performance measures
Mesh:
Year: 2017 PMID: 29183348 PMCID: PMC5706300 DOI: 10.1186/s13058-017-0917-3
Source DB: PubMed Journal: Breast Cancer Res ISSN: 1465-5411 Impact factor: 6.466
Number of screening examinations and mean measures
| Total | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | |
|---|---|---|---|---|---|---|
| Number of examinations | 132,776 | 26,490 | 26,617 | 26,539 | 26,549 | 26,581 |
| Mean breast volume (cm3) | 974 | 1511 | 1135 | 928 | 755 | 540 |
| Mean percent dense volume (%) | 7.8 | 5.7 | 6.6 | 7.5 | 8.4 | 10.7 |
| Mean force (N) | 125.9 | 112.6 | 121.5 | 125.9 | 130.7 | 138.9 |
| Mean pressure (kPa) | 10.5 | 6.6 | 8.5 | 10.0 | 11.8 | 15.6 |
Thresholds to form the groups were applied at 7.7 kPa, 9.3 kPa, 10.8 kPa, and 13 kPa
An examination with a pressure measurement equal to the threshold was assigned to the lower group
Fig. 1Measurements of force and pressure in relation to the breast volume. The color code represents the number of examinations in each bin. The horizontal lines in the right panel indicate the thresholds used to obtain the five pressure groups and the minimum and maximum pressure value observed
Number of screen-detected cancers, interval cancers, false positive examinations and true negative examinations
| Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total |
| % |
| % |
| % |
| % |
| % | |
| Total examinations | 132,776 | 26,490 | 20.0 | 26,617 | 20.0 | 26,539 | 20.0 | 26,549 | 20.0 | 26,581 | 20.0 |
| Screen detected cancers | 833 | 177 | 21.2 | 164 | 19.7 | 188 | 22.6 | 152 | 18.2 | 152 | 18.2 |
| Interval cancers | 269 | 37 | 13.8 | 48 | 17.8 | 48 | 17.8 | 65 | 24.2 | 71 | 26.4 |
| Interval cancers detected within 12 months after the examination | 110 | 19 | 17.3 | 15 | 13.6 | 13 | 11.8 | 26 | 23.6 | 37 | 33.6 |
| False positive examinations | 2192 | 486 | 22.2 | 381 | 17.4 | 404 | 18.4 | 426 | 19.4 | 495 | 22.6 |
| True negative examinations | 129,482 | 25,790 | 19.9 | 26,024 | 20.1 | 25,899 | 20.0 | 25,906 | 20.0 | 25,863 | 20.0 |
The 12-month interval cancers are included in the interval cancers
Unadjusted screening performance measurements
| Total | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | |
|---|---|---|---|---|---|---|
| Recall/1000 | 22.8 | 25.0 | 20.5 | 22.3 | 21.8 | 24.3 |
| False positives/1000 | 16.5 | 18.4 | 14.3 | 15.2 | 16.1 | 18.6 |
| Screen-detected cancers/1000 | 6.3 | 6.7 | 6.2 | 7.1 | 5.7 | 5.7 |
| Interval cancers/1000 | 2.0 | 1.4 | 1.8 | 1.8 | 2.5 | 2.7 |
| Program sensitivity (%) | 75.6 | 82.7 | 77.4 | 79.7 | 70.0 | 68.2 |
| 12-month sensitivity (%) | 88.3 | 90.3 | 91.6 | 93.5 | 85.4 | 80.4 |
| Specificity (%) | 98.3 | 98.2 | 98.6 | 98.5 | 98.4 | 98.1 |
| Positive predictive value (%) | 27.5 | 26.7 | 30.1 | 31.8 | 26.3 | 23.5 |
The sensitivity is calculated with all interval cancers, the 12-month sensitivity is calculated with the interval cancers that were detected within 12 months after the examination
Adjusted screening performance measurements with 95% confidence intervals using GEE to account for correlations between mammograms of the same woman and to correct for the confounders percent dense volume and breast volume
| Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | |
|---|---|---|---|---|---|
| Recall/1000 | 26.1 | 20.8 | 22.0 | 21.0 | 22.2 |
| False positives/1000 | 20.0 | 14.8 | 15.1 | 15.2 | 16.2 |
| Screen-detected cancers/1000 | 6.1 | 5.9 | 6.9 | 5.7 | 5.9 |
| Interval cancers/1000 | 1.3 | 1.6 | 1.6 | 2.2 | 2.3 |
| Program sensitivity (%)* | 82.0 | 77.1 | 79.8 | 71.1 | 70.8 |
| 12 month sensitivity (%)** | 90.1 | 92.0 | 93.9a
| 87.2 | 84.3a
|
| Specificity (%) | 98.0a,b,c
| 98.5a
| 98.5b
| 98.5c
| 98.4 |
| Positive predictive value (%) | 23.5 | 28.7 | 31.5 | 27.3 | 26.7 |
Pair-wise testing was applied on the sensitivity and specificity measurements and each subscript letter denotes a pair of pressure categories whose measurements differ significantly from each other
The Tukey method was used for correction for multiple testing and a p value below 0.05 was considered significant
The programm sensitivity (*) is calculated with all interval cancers, the 12-month sensitivity (**) is calculated with the interval cancers that were detected within 12 months after the examination
Fig. 2Measurements of 12-month sensitivity and specificity. Measurements of 12-month sensitivity and specificity of the five pressure groups of unadjusted data (squares) and after adjustment with generalized estimating equations (GEE) for multiple screening rounds, breast volume, and percent dense volume including 95% CI (circles). Statistically significant differences between pairs of groups of the GEE adjusted data are indicated